A n unprecedented push to coordinate biobanks in Europe is moving closer to completion, a project trumpeted as enabling researchers to discover cancer treatments more quickly by harnessing data from millions of biological samples.
The Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) wrapped up its 3-year preparatory phase in January, funded by a € 5 million grant from the European Union. The project recruited 270 associated organizations, mostly biobanks, potentially linking 20 million biological samples in 33 countries. A dozen charter member countries, including France and Italy, have raised another € 150 million to fi nance their biobanks ' participation as implementation of the project begins this year, according to BBMRI.
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Scientists hope BBMRI and other similar networks will help resolve certain obstacles to sharing information among biobanks, namely, the fragmentation due to countries ' different approaches to patient confi dentiality, informed consent, and data quality.
"We don't have any homogenization and standardization of consent forms for biobanking policies," said Arthur Caplan, a bioethicist at the University of Pennsylvania in Philadelphia. "We rather have a little bit of a Tower of Babel. Almost any company that collects tissue or genetic information comes up with its consent form and its privacy restrictions and its ownership or property disclaimers . . . They're all over the place, and we don't seem to be learning what works, what doesn't work in any systematic way."
Tens of thousands of biobanks operate around the world, ranging from freezers in hospitals to facilities that house millions of tissue samples, cells, blood, and other bodily fl uids along with the data that identify them. Public institutions such as hospitals and universities created most biobanks.
UK Biobank, Europe's largest public repository and a participant in BBMRI's preparatory phase, houses 10 million biological samples, including about 9,500 liters of blood and 2,500 liters of urine, in its storage facility at the University of Manchester. The specimens are kept in a giant freezer set at -80°C, consisting of a corridor 27 meters long between two 6-meter-high stacks of trays. A robotic arm roams the corridor at a speed of 2 meters per second, storing and retrieving the barcoded samples as needed.
Over the past 5 years, the governmentand charity-fi nanced biobank collected samples from about 500,000 people aged 40 -69 years in England, Scotland, and Wales -or about one of every 50 residents. The plan is to track their health over three decades to determine potential causes of widespread diseases such as cancer. "Having access to human cancer tissues is really the basis for all cancer research," said Kurt Zatloukal , professor of pathology at Austria's Medical University of Graz and coordinator of BBMRI's preparatory phase. "BBMRI now creates a framework where high-quality collaboration can be performed." The group's foremost challenge is now to forge closer ties among biobanks while preserving their individual norms and protecting donors ' rights.
Informed Consent
A key concern is the kind of consent needed from a donor in order to use his or her genetic material for research, particularly for future studies that can't be foreseen at the time someone provides a sample and signs a form. The trend in Europe has been for "broad consent" that places few limits on how a specimen may be later used, offering the greatest benefi t for researchers. Some bioethicists contend that a stricter approach to consent is needed to protect patient confi dentiality, including requiring researchers to return to the donor for additional authority for future studies, as tends to be the norm in the U.S.
Modern principles on the rights of research participants are rooted in the abuses of Nazi Germany exposed during the Nuremberg trials of doctors after World War II, which sentenced 16 doctors to prison or death for experimenting on humans. The resulting international guidelines emphasized protecting individual research participants over any broader societal aims that exist. In 2005, the United Nations Educational, Scientifi c, and Cultural Organization passed a declaration on bioethics and human rights that placed an individual's welfare above that of science or society.
"The interests and well-being of individuals should always, always prevail over the interests of science and society," said Jan Helge Solbakk, a professor at the Centre for Medical Ethics at the University of Oslo. "So-called new consent forms turn upside down this key principle."
Solbakk argues that the prevailing view among researchers on "informed consent" has become so diluted in the name of the potential benefi ts of biobanks that it has become virtually meaningless. Rather than simply seek the broadest consent possible, researchers should make donors "collaborative partners" in the process, said Solbakk, who also chairs the ethics and public policy committee of the International Society for Stem Cell Research.
"Providers of biological material and health information should not just be re duced to dollars; they should be brought in much more actively," he said. Routledge, 2008] ). In the U.S. as well, the consent and re-consent typically required, with the focus on individual rights, keeps donors more involved in the research projects.
Anonymizing Samples
Many biobanks handle the ethical challenges of a broad consent by "anonymizing" the data linked to the samples, in an effort to ensure that unauthorized individuals cannot trace the genetic material back to its source. The data are coded such that only a privileged "third party" has access. Who that third party is, from special panels to biobank-appointed committees, is the main issue, along with how much information the stored data reveal about the donor. Without the accompanying information, the genetic material is nearly worthless to researchers.
"The better we get at DNA analysis, almost any sample can lead to the identifi cation of someone," Caplan said. "Anonymization can go a long way toward handling it. I don't really think consent is practical. It just doesn't work. It hinders research too much."
Ensuring data safeguards via the thirdparty key holder coupled with stiff penalties for abuse are the best ways to protect donors while promoting research, he argues. 
N E W S
"We can never pretend that we can guarantee complete confi dentiality and privacy can't be infringed. It's not possible," Zatloukal admits."Anonymization of course reduces the risk but does not completely prevent it. One of the key principles of an informed consent is to really inform on this risk."
One primary way that BBMRI hopes to harmonize biobanks' using a wide variety of standards is by keeping biological samples in the country of origin and following local laws and guidelines on their handling and use. The samples would then be analyzed and the resulting data shared freely among researchers. "It's not the sample that's important, but the analysis," Zatloukal said.
Zatloukal set up focus groups throughout Europe to obtain feedback on the public perception of BBMRI. In addition, he surveyed 15,000 people via the European Com mission's Eurobarometer to learn what citizens think of consent, privacy, and other issues.
To improve the interoperability of biobanks, BBMRI followed a three-pronged approach that begins with the broad "best practices" guidelines set by the Organisation for Economic Co-operation and Development. The second stage involves creating standard operating procedures for each country that allow fl exibility while following international principles. Lastly, BBMRI will evaluate a sample ' 's data quality on a case by case basis, allowing that they don't have to be uniform to be useful as some contend. Operations should commence in the second half of 2012, Zatloukal said.
The project wasn't immune to the austerity plans sparked by the sovereign debt crisis spreading through Europe, forcing BBMRI to scale back its plans and slash its operating budget by about 30%, Zatloukal said. BBMRI, which forecasts costs of € 1.8 million in 2012, climbing to € 3 million in 2016, estimates that 70 projects will use its services in 2012, with that number increasing by about 20% annually for the next 5 years.
"The need for these biobanks is far more critical now, because they're going to help potentially a lot more people," said Gordon McVie, senior consultant at the European Institute of Oncology in Milan and a founding editor of ecancermedicalscience , an openaccess medical journal. Biobanks are going to be "unbelievably helpful to accelerate research into rare cancers."
Besides connecting biobanks, BBMRI is intended to link the public and nonprofi t role of most of the repositories with private companies, using so-called expert centers to get around European rules forbidding commercialization of human bodily materials. Samples from biobanks in the network will be analyzed at the centers, allowing the results of the research to be shared with private companies around the world, such as drug makers Pfi zer and Sanofi -Aventis, which have both expressed interest in the project, according to BBMRI.
The market for biological material has been soaring in recent years and is expected to continue to grow rapidly. For example, the global market for biomarkers, genetic indicators of a disease, is growing at almost 20%per year and should reach $20.5 billion by 2014, according to BBMRI.
Other Biobanking Networks
BBMRI isn't the only effort in Europe and elsewhere attempting to connect biobanks across countries and continents. EuroBioBank, TuBaFrost, and the Public Population Project in Genomics, also known as P3G, have all made progress establishing links among biobanks and navigating the disparate ethics, guidelines, and regulations that underlie the industry.
Zatloukal said it was important to involve other groups, such as TuBaFrost, a network of data-linked frozen cancer specimens, and EuroBioBank, which coordinates rare-disease biobanks, in the planning stages of BBMRI. The feeling was mutual.
"What they can learn from us is sharing bio materials across borders and being very open about what biomaterials we provide for research and how we interact with patient organizations and patients," said Hanns Lochmüller, scientifi c coordinator for EuroBioBank and professor of experimental myology at Newcastle University in the UK. "That's a major strength that we have in rare disorders and where we might be a bit ahead of the game."
Patients and researchers of rare disease created EuroBioBank in 2001 to offer access to relevant biological samples at biobanks across the region. The network, composed of 16 biobanks in eight European countries and coordinated by the patient-rights group EURORDIS, a patient advocacy group for rare diseases, currently boasts an online database listing more than 440,000 human DNA, cell, and tissue samples tied to rare diseases. The collaboration has helped researchers to develop therapies for diseases such as Duchenne muscular dystrophy, a rare disorder found only in young boys from which they normally die by their 30s or earlier, Lochmüller said. The treatment, which scientists in the U.S. and UK developed, involves fi xing the RNA between the genes rather than the gene itself. Biobanks using cells from patients with the disorder tested the method, which is now in clinical trials and "looks quite promising," he said.
"This is a very promising treatment in a very severe form of muscular dystrophy that has been developed on the back of biomaterial that patients have donated to biobanks," he said.
Maintaining Trust
A key consideration in developing biobanking networks is maintaining public trust by ensuring data confi dentiality. The potential consequences of using genetic material nefariously range from insurers ' refusing coverage to an individual whose genetic material suggests he or she is prone to a deadly disease or societies ' assigning status on the basis of a person's genes. Such concerns resonate in popular culture, such as with the 1997 sci-fi fi lm Gattaca , in which only people with perfect genes are allowed to attend the best schools and become astronauts.
The public also has to trust that harnessing large stores of genetic samples in biobanks is essential to making breakthroughs in medicine.
According to Solbakk, "The key asset of any research is trust. If trust is eroded, if both the providers of biological materials and health information and public institutions don't understand what is going on, this will backfi re."
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